Figure 5.
The sensitivities to irinotecan with modulating TOP1 and TDP1 expressions were evaluated by MTT assay. TOP1-siRNA mix, TDP1-siRNA mix, and non-targeting siRNA (160nM each) were transfected into olaparib-resistant cells or parental cells, and then treated with irinotecan for 5 d. Cell viability percentages were then measured by MTT assay, and TOP1 or TDP1 silencing was determined by western blotting (A,B). pCMV-tag2A-TOP1 or pCMV-tag2A-TDP1 and/or siTOP1 or siTDP1 were transfected into parental or olaparib-resistant cells. The sensitivity to irinotecan was calculated by MTT assay and the efficacy of transfection was confirmed by western blotting (C,D).